ONCY: Oncolytics Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Historical context for ONCY
Across the 22 sessions after earlier ONCY headlines, the stock closed higher 15 times and lower 7 times, with a median move of 3.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ONCY | SPY |
|---|---|---|---|
| May 22, 2026 | Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors | +2.5% | +0.4% |
| May 4, 2026 | Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer | +6.6% | -0.4% |
| Apr 27, 2026 | Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study | -6.0% | +0.2% |
| Apr 1, 2026 | Oncolytics Biotech® Completes Domicile Change to the United States | +9.6% | +0.8% |
| Mar 19, 2026 | Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026 | +1.9% | -0.2% |
| Mar 2, 2026 | Oncolytics Biotech® Launches Randomized Colorectal Cancer Study | -9.7% | +0.1% |
Quantisnow market dataNASDAQ
ONCY
Oncolytics Biotech Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for ONCY
Full ONCY profile on Quantisnow Follow ONCY and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time